CN105434555A - Production method of Relinqing preparation - Google Patents
Production method of Relinqing preparation Download PDFInfo
- Publication number
- CN105434555A CN105434555A CN201511017134.5A CN201511017134A CN105434555A CN 105434555 A CN105434555 A CN 105434555A CN 201511017134 A CN201511017134 A CN 201511017134A CN 105434555 A CN105434555 A CN 105434555A
- Authority
- CN
- China
- Prior art keywords
- relinqing
- thick paste
- add
- manufacture method
- herba polygoni
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a production method of a Relinqing preparation. The Relinqing preparation is prepared from Polygonum capitatum and auxiliary materials. According to properties of various medicinal materials in a formula of the Relinqing preparation as well as roles of the medicinal materials in the formula, the specific production method and parameters of the Relinqing preparation are improved, so that gallic acid used as an effective ingredient of the Polygonum capitatum can be detected easily, and the content of the measured gallic acid is high. Thus, the preparation is more refined and has the more significant efficacy and the good clinical effect.
Description
Technical field
The invention belongs to the field of Chinese medicines, be specifically related to a kind of manufacture method of 'Relinqing '.
Background technology
Chinese medicine extraction is a kind of method conventional in herbal pharmaceutical, and chemical composition of Chinese materia medica is extremely complicated, need extract the effective active ingredient of Chinese herbs of human body from the mixture of complexity.To improve drug effect.
Pyretic stranguria is made primarily of Herba Polygoni Capitati clearly.There is clearing away heat-fire, the fiery treating stranguria effect of profit.For diseases such as pyretic stranguria.
In prior art, pyretic stranguria is clearly make like this: get Herba Polygoni Capitati, cutting, add decocting in water secondary, each 1.5h, collecting decoction, leave standstill, filter, filtrate is condensed into thick paste, dry, pulverize, and adds right amount of auxiliary materials, and mixing, incapsulates, to obtain final product.But inventor finds in research process, adopt existing extraction process make pyretic stranguria clear in, the effective ingredient gallic acid of Herba Polygoni Capitati is not easily measured.The clinical efficacy making pyretic stranguria clear is desirable not enough.
Summary of the invention
The invention provides a kind of manufacture method of 'Relinqing '.The present invention is according to the character of medicine each in 'Relinqing ' prescription, and this medicine role in prescription, the concrete manufacture method of 'Relinqing ' and parameter are improved, the effective ingredient gallic acid of Herba Polygoni Capitati is easily measured, and the gallic acid content measured is high.Make the refine more of this medicine, drug effect is more remarkable, and clinical efficacy is good.
To achieve these goals, the invention provides following technical scheme: a kind of manufacture method of 'Relinqing ', get Herba Polygoni Capitati, cutting, add alcohol reflux, filter, decompression filtrate recycling ethanol, is concentrated into thick paste, dry, pulverize powdered; Add adjuvant, mixing, makes pharmaceutical preparation.
In the manufacture method of aforesaid 'Relinqing ', get Herba Polygoni Capitati, cutting, add 60-70% alcohol reflux 3-5 time of 8-12 times amount, each 1-2 hour, merging filtrate, filters, decompression filtrate recycling ethanol, when being concentrated into 60-70 DEG C, relative density is the thick paste of 1.10-1.20, and thick paste vacuum drying, gets dry extract, dry, pulverize powdered; Add adjuvant, make pharmaceutical preparation.
In the manufacture method of aforesaid 'Relinqing ', get Herba Polygoni Capitati, cutting, add 65% alcohol reflux 4 times of 10 times amount, each 1.5 hours, merging filtrate, filtered, decompression filtrate recycling ethanol, when being concentrated into 60-70 DEG C, relative density is the thick paste of 1.10-1.20, and thick paste vacuum drying, gets dry extract, dry, pulverize powdered; Add adjuvant, make pharmaceutical preparation.
In the manufacture method of aforesaid 'Relinqing ', described pharmaceutical preparation is oral formulations.
In the manufacture method of aforesaid 'Relinqing ', described oral formulations is capsule, tablet, granule or pill.
In the manufacture method of aforesaid 'Relinqing ', described capsule is prepared like this: get Herba Polygoni Capitati, cutting, add 65% alcohol reflux 4 times of 10 times amount, each 1.5 hours, merging filtrate, filtered, decompression filtrate recycling ethanol, when being concentrated into 60-70 DEG C, relative density is the thick paste of 1.10-1.20, and thick paste vacuum drying, gets dry extract, dry, pulverize powdered; Separately get the mixing of microcrystalline Cellulose, starch and magnesium stearate, obtain intermixture, the water adding intermixture 5% times amount in intermixture stirs into paste, as binding agent, binding agent mixes with powder, adds 75% ethanol of mixed powder powder amount 0.3 times amount, granulate, incapsulate, to obtain final product.
In the manufacture method of aforesaid 'Relinqing ', described tablet is prepared like this: get Herba Polygoni Capitati, cutting, add 65% alcohol reflux 4 times of 10 times amount, each 1.5 hours, merging filtrate, filtered, decompression filtrate recycling ethanol, when being concentrated into 60-70 DEG C, relative density is the thick paste of 1.10-1.20, and thick paste vacuum drying, gets dry extract, dry, pulverize powdered; Separately get microcrystalline Cellulose and starch mixing, obtain intermixture, the water adding intermixture 5% times amount in intermixture stirs into paste, and as binding agent, binding agent mixes with powder, adds 75% ethanol of mixed powder powder amount 0.3 times amount, granulates, and dry, tabletting, to obtain final product.
In the manufacture method of aforesaid 'Relinqing ', described granule is prepared like this: get Herba Polygoni Capitati, cutting, add 65% alcohol reflux 4 times of 10 times amount, each 1.5 hours, merging filtrate, filtered, decompression filtrate recycling ethanol, when being concentrated into 60-70 DEG C, relative density is the thick paste of 1.10-1.20, adds the cane sugar powder of the amount of making 50%, granulates, drying, to obtain final product.
In the manufacture method of aforesaid 'Relinqing ', described pill is prepared like this: get Herba Polygoni Capitati, cutting, add 65% alcohol reflux 4 times of 10 times amount, each 1.5 hours, merging filtrate, filtered, decompression filtrate recycling ethanol, when being concentrated into 60-70 DEG C, relative density is the thick paste of 1.10-1.20, and thick paste vacuum drying, gets dry extract, dry, pulverize powdered; Add the refined honey of the amount of making 10-20% and appropriate water, general ball, to obtain final product.
The present invention adopts Herba Polygoni Capitati to make medicine, i.e. 'Relinqing ', and the preparation made has clearing away heat-fire, the fiery treating stranguria effect of profit.For diseases such as pyretic stranguria.
The manufacture method method of existing production 'Relinqing ' is: get Herba Polygoni Capitati, adds decocting in water secondary, each 1.5h, collecting decoction, leaves standstill, and filter, filtrate is condensed into thick paste, dry, pulverize, and adds right amount of auxiliary materials, and mixing, incapsulates, to obtain final product.But inventor finds in research process, adopt make in this way pyretic stranguria clear in, the effective ingredient of Herba Polygoni Capitati is not easily measured.The clinical efficacy making pyretic stranguria clear is desirable not enough.Inventor also finds in technical study, and in the 'Relinqing ' adopting the inventive method to make, the effective ingredient of Herba Polygoni Capitati is easily measured, and the effective ingredient of the Herba Polygoni Capitati measured is high.This just makes the refine more of this medicine, and drug effect is more remarkable, and clinical efficacy is good.Therefore this technique facilitates the dissolution rate of the dissolution rate of effective ingredient in Herba Polygoni Capitati, particularly gallic acid, after the dissolution rate raising of gallic acid, effectively can improve the drug effect of 'Relinqing '.
Compared with prior art, in the 'Relinqing ' that the method for the invention makes, the effective ingredient gallic acid in Herba Polygoni Capitati is easily measured, and the gallic acid content measured is high.Effectively can improve the drug effect of 'Relinqing '.
Invention has been a large amount of experimentatioies, is below the result of experimentation of the present invention:
Experimental example 1: gallic acid content is investigated
1 raw material
1.1 pyretic stranguria of the present invention are clear, make by the method for embodiment 1.
1.2 existing pyretic stranguria are clear: make by following technique: get Herba Polygoni Capitati, cutting, add decocting in water secondary, each 1.5h, collecting decoction, leave standstill, and filter, filtrate is condensed into thick paste, dry, pulverize, and adds right amount of auxiliary materials, and mixing, incapsulates, to obtain final product.
1.3 instrument Ailent1100 type high performance liquid chromatographs, Agilent liquid chromatographic system chem workstation, AGl35 type electronic balance (Merrier.Toledo), CSF-lB ultrasonic washing instrument.
Gallic acid reference substance (Nat'l Pharmaceutical & Biological Products Control Institute. lot number 110831-200302), methanol is chromatographically pure, and water is pure water, and all the other reagent are analytical pure.
2 experimental techniques and result
2.1 chromatographic condition
Dionsil
tM(diamond) post C18 (4.6mm × 250mm, 5um), mobile phase methanol-water-DMF-glacial acetic acid (1:95:3:1), column temperature 25 DEG C, determined wavelength 272nm, flow velocity 1.0mL/min.Number of theoretical plate is pressed gallic acid peak and is calculated, and is not less than 2000.
2.2 solution preparations
The preparation of reference substance solution: the close gallic acid reference substance that takes is appropriate, adds 50% methanol and makes the solution of every 1mL containing 0.07mg, to obtain final product.
The preparation of need testing solution 1: get Relinqing capsules of the present invention, porphyrize, gets about 0.2g, accurately weighed, put in 25mL measuring bottle, add 50% methanol 20mL, supersound process 1h (power 250W, frequency 40KHz), lets cool, add 50% methanol to scale, shake up, leave standstill, filter, filtrate crosses the microporous filter membrane of 0.45um, to obtain final product.
The preparation of need testing solution 2: enchashment has the clear Relinqing capsules of pyretic stranguria, porphyrize gets about 0.2g, accurately weighed, put in 25mL measuring bottle, add 50% methanol 20mL, supersound process 1h (power 250W, frequency 40KHz), lets cool, add 50% methanol to scale, shake up, leave standstill, filter, filtrate crosses the microporous filter membrane of 0.45um, to obtain final product.
2.3 assay method
Close absorption reference substance solution, need testing solution 1 and each 10ul of need testing solution 2, inject chromatography and measure, to obtain final product.
2.4 linear relationships are investigated
Draw the reference substance solution 1,2,4,6,8,10ul that concentration is 0.1396g/L, injection liquid chromatography, measures by fixed chromatographic condition, record peak area.With the micrograms of reference substance for abscissa, peak area is vertical coordinate drawing standard curve, its regression equation A=2872.0042C+0.362466 (r=0.99997), and result shows that gallic acid is linearly good at 0.1396 ~ 1.396ug.
2.5 precision test
Accurate absorption gallic acid reference substance solution 10ul, repeats sample introduction 6 times, measures the peak area of gallic acid by fixed chromatographic condition respectively.Result RSD=0.23%.Illustrate that the precision of instrument is good.
2.6 replica test
Precision takes existing 'Relinqing ' and each 6 parts of existing 'Relinqing ' respectively, by need testing solution preparation method and chromatographic condition, and result RSD=0.44%.Result shows that the method repeatability is good.
2.7 stability tests get need testing solution 1 and need testing solution 2 respectively, by fixed chromatographic condition, respectively 0, and 1,2,4,6,8h measures, and the RSD of result gallic acid peak area is 0.46% and 0.50%, shows that need testing solution 1 and need testing solution 2 are stable in 8h.
2.8 average recovery tests
Precision takes the 'Relinqing ' of the present invention of known content and existing 'Relinqing ' respectively, make need testing solution 1 and need testing solution 2, add appropriate gallic acid reference substance solution, measure by fixed chromatographic condition, calculate the response rate, result average recovery rate is 97.86% and RSD=0.73%.Illustrate that fixed method has the good response rate, can be used for the content measuring gallic acid in Relinqing Granula.
2.10 sample size measures
Get 'Relinqing ' of the present invention and existing 'Relinqing ' respectively, accurately weighed, by need testing solution 1 and the preparation of need testing solution 2 preparation method, parallelly measure 6 parts, draw 10 microlitres respectively by chromatographic condition, sample introduction analysis, by the content calculating gallic acid, the results are shown in Table 1.
The assay result of table 1 gallic acid
As known from Table 1, in 'Relinqing ' of the present invention, the average content of gallic acid is 8.01mg/g, and in existing 'Relinqing ', the average content of gallic acid is 7.55mg/g.
Conclusion: compared with existing 'Relinqing ', in 'Relinqing ' of the present invention, the content of the effective ingredient gallic acid of Herba Polygoni Capitati is higher.In like manner, the preparation of other dosage forms made according to extracting method of the present invention, the active constituent content of Herba Polygoni Capitati also should increase.
Experimental example 2: Effect tests
1 experiment material
1.1 medicine
1.1.1 pyretic stranguria of the present invention is clear, with embodiment 1..
1.1.2 existing pyretic stranguria is clear, with experimental example 1.
1.2 laboratory animal Kunming mouses, rat (Wistar) are primary animal (quality certification number: dynamic No. the 310101001st, 310101002, the word of doctor), are provided by Animal Experimental Study room, Chongqing Institute of Chinese Medicine.Experimental work is carried out (the facility quality certification number: No. 20000330) at primary standard Animal Lab..
1.3 animal SD rats, male and female have concurrently, body weight 200 ~ 250g, are provided by Sichuan Industrial Institute of Antibiotics's Experimental Animal Center, the animal quality certification number: real dynamic No. 99-32nd, the pipe word in river.Animal feeding room condition: (20 ± 1) DEG C, relative humidity 60% ~ 70%, freely drinks water and searches for food.
2 experimental techniques
Rat 200-250g, lumbar injection pentobarbital sodium 30mg/kg anaesthetize.Prostrate fixing, dorsal part cuts, and fully exposes the right kidney of dew, adopts 0.25mL capacity Bacillus Calmette-Guérin syringe in kidney substantial part, point 3 places inoculation 10
7/ rnL bacterium liquid 50 microlitre, the postoperative metabolic cage that is placed in is raised separately.Collect the fresh urine sample of postoperative 24h, leukocyte count in urine sample is recorded under the microscope with blood cell counting plate, leukocyte count in every cubic millimeter of urine sample is person more than 100, be considered as the success of bacterial nephritis model, by model mouse by the leukocyte count in urine and sex random packet, invention formulation group, existing preparation group and model group, establish Normal group (non-bacterial infection person) simultaneously.After animal grouping, namely gavage gives corresponding test medicine, model group ig isometric(al) normal saline, successive administration 7d, collects urine sample before sky administration, the leukocyte count in counting urine sample; Non parametric method is adopted to carry out statistical analysis; Numeration of leukocyte statistical disposition in urine adopts t inspection, and compare the difference of administration group and model group, above-mentioned process all adopts computer SPPSS software to analyze.
3 results
3.1 pyretic stranguria clearly on the impact from cell in bacterial nephritis rat urine, in table 2 and table 3.
Rat bacterial nephritis in this test can recover voluntarily, and invention formulation group and existing preparation group are replied and be obviously better than model group, and invention formulation group effect is better than existing preparation group.After administration the 2nd, 3,4,5,6,7d, the quantity of leucocyte in this group rat urine is obviously less than model group.
The leukocytic impact of table 2 pyelonephritis rat urine ((
n=8)
Note: compare with model group, * P<0.05, * * P<0.01; Compare with existing preparation group
+p<0.05.
The leukocytic impact of table 3 pyelonephritis rat urine ((
n=8)
Note: compare with model group, * P<0.05, * * P<0.01; Compare with existing preparation group
+p<0.05.
Conclusion, 'Relinqing ' of the present invention and existing 'Relinqing ' all have good therapeutical effect to bacterial nephritis rat, and 'Relinqing ' effect of the present invention is better than existing 'Relinqing '.
Detailed description of the invention:
Embodiment 1:
Get Herba Polygoni Capitati, cutting, add 65% alcohol reflux 4 times of 10 times amount, each 1.5 hours, merging filtrate, filters, decompression filtrate recycling ethanol, and when being concentrated into 60-70 DEG C, relative density is the thick paste of 1.10-1.20, thick paste vacuum drying, gets dry extract, and dry, pulverize powdered; Separately get the mixing of microcrystalline Cellulose, starch and magnesium stearate, obtain intermixture, the water adding intermixture 5% times amount in intermixture stirs into paste, as binding agent, binding agent mixes with powder, adds 75% ethanol of mixed powder powder amount 0.3 times amount, granulate, incapsulate, obtain capsule.
Usage and dosage: oral, a 3-4 grain, 3 times on the one.
Specification: 0.35g/ grain.
Storage: sealing.
Embodiment 2:
Get Herba Polygoni Capitati, cutting, add 65% alcohol reflux 4 times of 10 times amount, each 1.5 hours, merging filtrate, filters, decompression filtrate recycling ethanol, and when being concentrated into 60-70 DEG C, relative density is the thick paste of 1.10-1.20, thick paste vacuum drying, gets dry extract, and dry, pulverize powdered; Separately get microcrystalline Cellulose and starch mixing, obtain intermixture, the water adding intermixture 5% times amount in intermixture stirs into paste, and as binding agent, binding agent mixes with powder, adds 75% ethanol of mixed powder powder amount 0.3 times amount, granulates, and dry, tabletting, obtains tablet.
Usage and dosage: oral, a 3-4 sheet, 3 times on the one.
Specification: 0.35g/ sheet.
Storage: sealing.
Embodiment 3:
Get Herba Polygoni Capitati, cutting, add 65% alcohol reflux 4 times of 10 times amount, each 1.5 hours, merging filtrate, filters, decompression filtrate recycling ethanol, and when being concentrated into 60-70 DEG C, relative density is the thick paste of 1.10-1.20, add the cane sugar powder of the amount of making 50%, granulate, dry, obtain granule.
Usage and dosage: oral, a 5-10g, 3 times on the one.
Specification: 5g/ bag.
Storage: sealing.
Claims (9)
1. a manufacture method for 'Relinqing ', is characterized in that: get Herba Polygoni Capitati, cutting, adds alcohol reflux, and filter, decompression filtrate recycling ethanol, is concentrated into thick paste, dry, pulverize powdered; Add adjuvant, mixing, makes pharmaceutical preparation.
2. the manufacture method of 'Relinqing ' as claimed in claim 1, is characterized in that: get Herba Polygoni Capitati, cutting, add 60-70% alcohol reflux 3-5 time of 8-12 times amount, each 1-2 hour, merging filtrate, filters, decompression filtrate recycling ethanol, when being concentrated into 60-70 DEG C, relative density is the thick paste of 1.10-1.20, and thick paste vacuum drying, gets dry extract, dry, pulverize powdered; Add adjuvant, make pharmaceutical preparation.
3. the manufacture method of 'Relinqing ' as claimed in claim 2, is characterized in that: get Herba Polygoni Capitati, cutting, add 65% alcohol reflux 4 times of 10 times amount, each 1.5 hours, merging filtrate, filtered, decompression filtrate recycling ethanol, when being concentrated into 60-70 DEG C, relative density is the thick paste of 1.10-1.20, and thick paste vacuum drying, gets dry extract, dry, pulverize powdered; Add adjuvant, make pharmaceutical preparation.
4. the manufacture method of the 'Relinqing ' according to any one of claim 1-3, is characterized in that: described pharmaceutical preparation is oral formulations.
5. the manufacture method of 'Relinqing ' as claimed in claim 5, is characterized in that: described oral formulations is capsule, tablet, granule or pill.
6. the manufacture method of 'Relinqing ' as claimed in claim 5, is characterized in that: described capsule is prepared like this: get Herba Polygoni Capitati, cutting, enter 65% alcohol reflux 4 times of 10 times amount, each 1.5 hours, merging filtrate, filtered, decompression filtrate recycling ethanol, when being concentrated into 60-70 DEG C, relative density is the thick paste of 1.10-1.20, and thick paste vacuum drying, gets dry extract, dry, pulverize powdered; Separately get the mixing of microcrystalline Cellulose, starch and magnesium stearate, obtain intermixture, the water adding intermixture 5% times amount in intermixture stirs into paste, as binding agent, binding agent mixes with powder, adds 75% ethanol of mixed powder powder amount 0.3 times amount, granulate, incapsulate, to obtain final product.
7. the manufacture method of 'Relinqing ' as claimed in claim 5, is characterized in that: described tablet is prepared like this: get Herba Polygoni Capitati, cutting, add 65% alcohol reflux 4 times of 10 times amount, each 1.5 hours, merging filtrate, filtered, decompression filtrate recycling ethanol, when being concentrated into 60-70 DEG C, relative density is the thick paste of 1.10-1.20, and thick paste vacuum drying, gets dry extract, dry, pulverize powdered; Separately get microcrystalline Cellulose and starch mixing, obtain intermixture, the water adding intermixture 5% times amount in intermixture stirs into paste, and as binding agent, binding agent mixes with powder, adds 75% ethanol of mixed powder powder amount 0.3 times amount, granulates, and dry, tabletting, to obtain final product.
8. the manufacture method of 'Relinqing ' as claimed in claim 5, is characterized in that: described granule is prepared like this: get Herba Polygoni Capitati, cutting, add 65% alcohol reflux 4 times of 10 times amount, each 1.5 hours, merging filtrate, filtered, decompression filtrate recycling ethanol, when being concentrated into 60-70 DEG C, relative density is the thick paste of 1.10-1.20, adds the cane sugar powder of the amount of making 50%, granulates, drying, to obtain final product.
9. the manufacture method of 'Relinqing ' as claimed in claim 5, is characterized in that: described pill is prepared like this: get Herba Polygoni Capitati, cutting, add 65% alcohol reflux 4 times of 10 times amount, each 1.5 hours, merging filtrate, filtered, decompression filtrate recycling ethanol, when being concentrated into 60-70 DEG C, relative density is the thick paste of 1.10-1.20, and thick paste vacuum drying, gets dry extract, dry, pulverize powdered; Add the refined honey of the amount of making 10-20% and appropriate water, general ball, to obtain final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201511017134.5A CN105434555A (en) | 2015-12-30 | 2015-12-30 | Production method of Relinqing preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201511017134.5A CN105434555A (en) | 2015-12-30 | 2015-12-30 | Production method of Relinqing preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105434555A true CN105434555A (en) | 2016-03-30 |
Family
ID=55545489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201511017134.5A Pending CN105434555A (en) | 2015-12-30 | 2015-12-30 | Production method of Relinqing preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105434555A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107375449A (en) * | 2017-09-02 | 2017-11-24 | 合肥今越制药有限公司 | A kind of new application of the clear piece of heat gonorrhea |
| CN107496515A (en) * | 2017-09-02 | 2017-12-22 | 合肥今越制药有限公司 | A kind of preparation method for treating heat gonorrhea medicine |
| CN110464755A (en) * | 2019-09-17 | 2019-11-19 | 河南百年康鑫药业有限公司 | A kind of Chinese medicine composition tablet for treating acute pyelonephritis |
| CN111714551A (en) * | 2019-10-24 | 2020-09-29 | 贵州益佰女子大药厂有限责任公司 | Preparation method of stranguria-treating preparation |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1481832A (en) * | 2002-09-12 | 2004-03-17 | 贵州威门药业股份有限公司 | Polygonum capitatum extract and preparation method and application thereof |
| CN1483466A (en) * | 2002-07-12 | 2004-03-24 | 贵州威门药业股份有限公司 | Polygonum capitatum extract and medicinal composition preparation thereof |
| CN101940625A (en) * | 2010-09-07 | 2011-01-12 | 中国中医科学院中药研究所 | Preparation method and use of extract |
| CN102526219A (en) * | 2012-01-05 | 2012-07-04 | 贵州威门药业股份有限公司 | Extract for Relinqing Granule, as well as preparation method and application of same |
| CN102526218A (en) * | 2012-01-05 | 2012-07-04 | 贵州威门药业股份有限公司 | Method for preparing Polygonum capilalum extract and Polygonum capilalum extract |
| CN102653537A (en) * | 2012-05-17 | 2012-09-05 | 中国人民解放军第九七医院 | Method for extracting and preparing high-purity silibinin from polygonum capitatum herb |
| CN102659549A (en) * | 2012-04-01 | 2012-09-12 | 贵州威门药业股份有限公司 | Method for extracting brevifolin from Relinqing granula raw material and method for preparation quality control |
| CN102772499A (en) * | 2012-08-22 | 2012-11-14 | 贵州威门药业股份有限公司 | Effective parts obtained by alcohol extraction of raw materials of Relingqing granules as well as preparation method and applications thereof |
| CN103536663A (en) * | 2013-10-30 | 2014-01-29 | 浙江百草中药饮片有限公司 | Preparation method of polygonum capitatum sugar reduction extract tablet |
-
2015
- 2015-12-30 CN CN201511017134.5A patent/CN105434555A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1483466A (en) * | 2002-07-12 | 2004-03-24 | 贵州威门药业股份有限公司 | Polygonum capitatum extract and medicinal composition preparation thereof |
| CN1481832A (en) * | 2002-09-12 | 2004-03-17 | 贵州威门药业股份有限公司 | Polygonum capitatum extract and preparation method and application thereof |
| CN101940625A (en) * | 2010-09-07 | 2011-01-12 | 中国中医科学院中药研究所 | Preparation method and use of extract |
| CN102526219A (en) * | 2012-01-05 | 2012-07-04 | 贵州威门药业股份有限公司 | Extract for Relinqing Granule, as well as preparation method and application of same |
| CN102526218A (en) * | 2012-01-05 | 2012-07-04 | 贵州威门药业股份有限公司 | Method for preparing Polygonum capilalum extract and Polygonum capilalum extract |
| CN102659549A (en) * | 2012-04-01 | 2012-09-12 | 贵州威门药业股份有限公司 | Method for extracting brevifolin from Relinqing granula raw material and method for preparation quality control |
| CN102653537A (en) * | 2012-05-17 | 2012-09-05 | 中国人民解放军第九七医院 | Method for extracting and preparing high-purity silibinin from polygonum capitatum herb |
| CN102772499A (en) * | 2012-08-22 | 2012-11-14 | 贵州威门药业股份有限公司 | Effective parts obtained by alcohol extraction of raw materials of Relingqing granules as well as preparation method and applications thereof |
| CN103536663A (en) * | 2013-10-30 | 2014-01-29 | 浙江百草中药饮片有限公司 | Preparation method of polygonum capitatum sugar reduction extract tablet |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107375449A (en) * | 2017-09-02 | 2017-11-24 | 合肥今越制药有限公司 | A kind of new application of the clear piece of heat gonorrhea |
| CN107496515A (en) * | 2017-09-02 | 2017-12-22 | 合肥今越制药有限公司 | A kind of preparation method for treating heat gonorrhea medicine |
| CN110464755A (en) * | 2019-09-17 | 2019-11-19 | 河南百年康鑫药业有限公司 | A kind of Chinese medicine composition tablet for treating acute pyelonephritis |
| CN110464755B (en) * | 2019-09-17 | 2021-07-20 | 河南百年康鑫药业有限公司 | A Chinese medicinal tablet for treating acute pyelonephritis |
| CN111714551A (en) * | 2019-10-24 | 2020-09-29 | 贵州益佰女子大药厂有限责任公司 | Preparation method of stranguria-treating preparation |
| CN111714551B (en) * | 2019-10-24 | 2021-10-15 | 贵州益佰女子大药厂有限责任公司 | Preparation method of stranguria-treating preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101422563B (en) | Traditional Chinese medicine composition for treating wean sphagitis and preparation method and quality control method thereof | |
| CN101984983B (en) | Detection method of Lamiophlomis rotata extract, medicine composition containing the extract | |
| CN105434555A (en) | Production method of Relinqing preparation | |
| CN104730171B (en) | Radix Paeoniae Rubra, Flos Lonicerae multi-target ingredient content assaying method in a kind of compound Chinese medicinal preparation | |
| CN104345111A (en) | Determination method for content of multiple active compositions in traditional Chinese medicine composition preparation | |
| WO2019072247A1 (en) | Ultra-high-performance liquid chromatography detection method for traditional chinese medicine composition | |
| CN100518768C (en) | Cassia twig tuckahoe effervescence tablet and testing method | |
| CN102058814B (en) | General flavone extractive of four medicaments including grassleaf sweetflag rhizome and preparation method thereof | |
| CN101502549B (en) | Notoginsen triterpenes capsule as well as preparation method thereof and method for measuring content | |
| CN102784275B (en) | Tongzhisurunjiang tablet for activating retardation and softening and preparation and quality control method thereof | |
| CN103191198A (en) | Rhizoma corydalis extract as well as preparation method and use thereof | |
| CN101816693B (en) | Echinacea purpurea extract powder and preparation method and application thereof | |
| CN103675135B (en) | A kind of content assaying method of Chinese medicine composition | |
| CN105497713A (en) | Preparation method of inflammation diminishing and cough relieving preparation | |
| CN103575823B (en) | The detection method of 8 kinds of chemical compositions in a kind of Tangminling preparation | |
| CN110243986A (en) | A kind of goitre piece HPLC finger-print and preparation method thereof that disappears of invigorating blood circulation | |
| CN101766664A (en) | Extraction method of total saponin of Radix Ilicis Asprellae and quality detection method thereof | |
| CN103110890B (en) | Effective part of Xierigasiwei (Mongolian medicine) as well as preparation method, quality detection method and application thereof | |
| CN105497156A (en) | Preparation method of fleeceflower root life-extending preparation | |
| CN105560809A (en) | Production process of preparation containing radix ophiopogonis, processed schisandra chinensis and prepared rehmannia root | |
| CN101744887A (en) | Detection Method for Chinese medicinal composition preparation | |
| CN104345115B (en) | A kind of method for qualitative and quantitative detection of Kanggu-Zengsheng tablet | |
| CN103405664A (en) | Daochi powder formula granule as well as preparation method, use and detection method thereof | |
| CN105497499B (en) | A kind of production method of Maiwei-dihuang preparation | |
| CN101757093A (en) | Detection method of traditional Chinese medicine composition preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160330 |
|
| RJ01 | Rejection of invention patent application after publication |